Skip to main content

Drug Interactions between Attruby and fosphenytoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fosphenytoin acoramidis

Applies to: fosphenytoin and Attruby (acoramidis)

GENERALLY AVOID: Coadministration with inducers of uridine diphosphoglucuronate-glucuronosyltransferase (UGT) enzymes and potent inducers of CYP450 3A4 isoenzymes may decrease the plasma concentrations of acoramidis. In vitro, acoramidis is a substrate of multiple UGT enzymes including UGT1A9, UGT1A1, and UGT2B7 and is primarily metabolized by UGT enzyme-mediated glucuronidation. Acoramidis beta-D-glucuronide (Acoramidis-AG) is the predominant metabolite of acoramidis. Acoramidis-AG is approximately 1/3 as pharmacologically active compared with acoramidis, has a low potential for covalent binding, and does not contribute to pharmacological activity. While acoramidis is not metabolized by CYP450 3A4, strong CYP450 3A4 inducers can also induce UGT enzymes.

MANAGEMENT: According to the manufacturer, concomitant use of acoramidis with inducers of UGT enzymes and potent inducers of CYP450 3A4 should generally be avoided due to the potential for reduced efficacy.

References (1)
  1. (2024) "Product Information. Attruby (acoramidis)." BridgeBio Pharma, Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer